EICHOR
● Recruiting
Interaction Between Gut Microbiota and TKIs in Defining the Clinical Outcomes of Patients With CML
Condition: Leukemia,Myeloid, Chronic · Sponsor: Carmen Fava
About this study
Gut microbiome (GM) is acquiring increasing importance in human health and disease. GM influences hematopoiesis and immune cells types differentiation. Patients with cancer are characterized by dysbiosis and compromised immunity. In the case of Chronic Myeloid Leukemia (CML), treatment with Tyrosine Kinase Inhibitors (TKIs) restores immunosurveillance; in particular deep molecular response (DMR) is associated with increased levels of NK and CD8+ Tcells. There is no literature on the effects of GM on CML outcomes. This project aims to identify a microbial signature associated with a higher probability of achieving DMR.
This description comes directly from the study's public registry record.
Talk to the study team
Carmen Fava · 00390115082224 · carmen.fava@unito.it
Valentina Bonuomo · 00390115082224
Always discuss trial participation with your own doctor first.
Locations (1)
| AO Ordine Mauriziano di Torino | Torino, Italy | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06724536